Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

The Use and Clinical Significance of Transcranial Magnetic Stimulation in the Treatment of Major Depression

Demitrack, Mark A. MD

Section Editor(s): Janicak, Philip G. MD

doi: 10.1097/01.IDT.0000271143.75925.33
Article
Buy
CME

Dr. Demitrack is Vice President and Chief Medical Officer, Neuronetics, Inc., One Great Valley Parkway, Suite 2, Malvern, PA 19355; E-mail: mdemitrack@neuronetics.com.

The author has disclosed that he is a stock shareholder of Neuronetics, Inc., Eli Lilly, and Wyeth Pharmaceuticals.

The author also has disclosed that the use of the NeuroStar TMS Therapy System as well as the use of estrogen, ketoconazole, lorazepam, and lithium carbonate has not been approved by the U.S. Food and Drug Administration for the treatment of major depression.

© 2007 by Lippincott Williams & Wilkins, Inc.
You currently do not have access to this article

To access this article:

Note: If your society membership provides full-access, you may need to login on your society website